|BioTime to Present Data from OpRegen® Phase I/IIa Clinical Study at the Association for Research in Vision and Ophthalmology Annual Meeting (ARVO 2019)|
April 16, 2019
|ALAMEDA, Calif.--(BUSINESS WIRE)--Apr. 16, 2019--
Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology
company developing new cellular therapies, announced today that updated
results from a Phase I/IIa clinical study of its lead product candidate,
OpRegen®, a retinal pigment epithelium (RPE) cell transplant
therapy currently in development for the treatment of dry age-related
macular degeneration (AMD) with geographic atroph... |
|OncoCyte Provides Corporate Update and Reports Fourth Quarter and Full Year 2018 Financial Results|
April 01, 2019
|On track for commercial availability of DetermaVu™ in 2H 2019
Conference Call Today at 4:30 PM EDT
ALAMEDA, Calif., April 01, 2019 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive tests for the early detection of lung cancer, today reported financial and operating results for the fourth quarter and year ended December 31, 2018 and provided a corporate update.
“OncoCyte has made outstanding progress since our last quarterly update to investor... |
|OncoCyte to Present Late Breaking Abstract at the American Thoracic Society 2019 International Conference|
April 01, 2019
|Poster presentation and discussion to detail compelling results from R&D Validation study of the Company’s DetermaVu™ liquid biopsy test for the early detection of lung cancer
ALAMEDA, Calif., April 01, 2019 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive tests for the early detection of cancer, today announced that a late breaking abstract has been accepted for a poster presentation and discussion session at the American Thoracic Society 2019... |
View Committee Composition
Find the latest financial information
DISCLAIMER: You are about to review presentations, reports, filings and/or other materials regarding BioTime, Inc. (NYSE: MKT and TASE: BTX) that contain time-sensitive information. The information contained therein is only current as of the date thereof. BioTime expressly disclaims any obligation to review, update or correct these materials after the date thereof. BioTime may update, amend, supplement or otherwise alter the information contained in any such materials by subsequent presentations, reports, filings, or other means without notice.
Certain statements made on this website or in materials accessed in or through this section of our website are "forward-looking statements," which are subject to risks and uncertainties, and BioTime's actual results may differ (possibly materially) from those indicated in such statements.
|Data provided by Nasdaq. Minimum 15 minutes delayed.|